Affiliation:
1. Southern Medical University
2. Sichuan Agricultural University
3. Guangzhou Beneco Biotechnology Co. Ltd
4. Tibet University
Abstract
Abstract
Background
Hyperuricemia (HUA) is a prevalent metabolic disorder globally, and its development is increasingly associated with intestinal microbiota. Therefore, probiotics have emerged as a potential and safe approach for lowering uric acid (UA) levels. However, effective probiotic strains and the underlying mechanism remain unknown.
Purpose
This study aims to investigate microbiota alterations in each intestinal segment during HUA to identify the most affected segment and potential probiotic strains.
Methods
This study contains two animal experiments. In the first animal experiment, male SD rats were randomly divided into two groups and administered with either 0.5%CMC (Control group) or potassium oxonate (Model group) by oral gavage for an 84-days period. After sacrifice, the whole Gut microbiota was analyzed. In the ssecond animal experiment,Male SD rats were randomly divided into three groups with Control and model groups treated the same as former experiment, while YH1136 group was treated by Lactobacillus johnsonii YH1136 instead (daily amounts of 2×108 CFU).
Results
Whole intestinal diversity was significantly decreased in the model group than in the control, with the most significant decrease in the cecum and colon. Firmicutes, Bacteroidota, and Actinobacteriota were the dominant phyla common to the control and model groups, whereas Bacteroidota was more dominant in the colon of the model group than in the control group. In the RDA analysis, Lactobacillus in the colon and the model group exhibited a strong correlation, suggesting that Lactobacillus may play an important role in hyperuricemia. Consequently, Lactobacillus johnsonii YH1136 was used to assess its preventive effects against HUA. The results showed that Lactobacillus johnsonii YH1136 administration effectively reduced serum UA levels in vivo, mainly inhibiting hepatic xanthine oxidas(XOD) activity and promoting renal ABCG2 transporter expression.Moreover, increased colonization using Lactobacillus johnsonii YH1136 significantly ameliorated pathological damage in the kidney and liver, causing UA accumulation.
Conlusion
These findings highlight the potential significance of Lactobacillus as a connection between HUA and the gut microbiota, providing compelling evidence for Lactobacillus johnsonii YH1136 as a potential treatment for HUA.
Publisher
Research Square Platform LLC
Reference69 articles.
1. Major TJ, Topless RK, Dalbeth N, Merriman TR (2018) Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. BMJ. ;363:k3951. Epub 2018/10/12. doi: 10.1136/bmj.k3951. PubMed PMID: 30305269; PubMed Central PMCID: PMCPMC6174725 at www.icmje.org/coi_disclosure.pdf and declare: ND has received consulting fees, speaker fees, or grants from the following companies who have developed or marketed urate lowering drugs for management of gout: Takeda, Ardea Biosciences/AstraZeneca, Cymabay/Kowa, and Crealta/Horizon. TRM has received grants from Ardea Biosciences/AstraZeneca and Ironwood Pharmaceuticals
2. A prescription for lifestyle change in patients with hyperuricemia and gout;Choi HK;Curr Opin Rheumatol,2010
3. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK (2019) Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal. Arthritis Rheumatol 71(6):991–999 Epub 2019/01/09. 10.1002/art.40807. Trends: The National Health and Nutrition Examination Survey, 2007–2016
4. Prevalence of Hyperuricemia Among Chinese Adults: Findings From Two Nationally Representative Cross-Sectional Surveys in 2015-16 and 2018-19;Zhang M;Front Immunol,2021
5. Urate Handling in the Human Body;Hyndman D;Curr Rheumatol Rep,2016